Adrenomed

Adrenomed is a clinical-stage biotech pioneering a precision medicine approach for acute care, specifically targeting septic shock. Its lead asset, enibarcimab, is a first-in-class antibody designed to restore vascular integrity by modulating the vasoprotective peptide adrenomedullin. The company has generated promising Phase II data using a biomarker-guided strategy and has secured FDA Fast Track designation, positioning it to address a critical unmet medical need with a targeted therapeutic. It remains a privately held company backed by venture capital investors.

Precision medicine platform targeting vascular integrity via the adrenomedullin (ADM) pathway. Utilizes a first-in-class antibody (enibarcimab) that stabilizes endogenous ADM to restore endothelial barrier function. Employs a dual-biomarker (bio-ADM and DPP3) companion diagnostic strategy to identify responsive patients.

The competitive landscape for novel septic shock therapies is sparse, with decades of high-profile clinical failures. Competition includes other biotechs exploring immunomodulation or coagulation pathways (e.g., Inotrem, InflaRx), but few have a similarly advanced, biomarker-defined antibody approach. The main competition is the current standard of care (antibiotics, fluids, vasopressors), against which any new therapy must demonstrate clear added benefit.